Advances in genome sequencing technology are allowing researchers to study why some patients respond well to treatments that fail in others with the same disease. The research could lead to new uses for existing and abandoned compounds, researchers say. Projects are planned or underway at the National Cancer Institute, Memorial Sloan-Kettering Cancer Center, MD Anderson Cancer Center and Dana-Farber Cancer Institute, among others.

Full Story:

Related Summaries